Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

AbstractOvarian cancer is often limited to the peritoneal cavity in the form of peritoneal carcinomatosis. Peritoneal spreading offers the opportunity for locoregional delivery of combinations of immunotherapy agents, maximizing bioavailability while potentially reducing systemic exposure and side effects.See related article by Orr et al., p. 2038

Original publication

DOI

10.1158/1078-0432.ccr-22-0201

Type

Journal article

Journal

Clinical Cancer Research

Publisher

American Association for Cancer Research (AACR)

Publication Date

13/05/2022

Volume

28

Pages

1993 - 1995